AHEP1531 - Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT), A Phase 2/3 Study, An Intergroup Study by Société Internationale d’Oncologie Pédiatrique (SIOPEL) in collaboration with COG and the Japanese

s phase 2/3 study is examining the best treatments for pediatric liver tumors. It is looking to improve survival for patients with a poor prognosis while potentially reducing therapy and the risk for side effects in patients with good prognoses. Hepatoblastoma and hepatocellular carcinoma are the liver tumors being studied.

Are you Eligible? (Inclusion Criteria)

• Patients must be 30 years of age or younger
• Patients must have not previously received treatment for either hepatoblastoma or hepatocellular carcinoma
• Patients must also meet all eligibility criteria as outlined in the study protocol, including sub-study criteria.